The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
Open accessAbstract
Recurrence of Clostridium difficile infection (CDI) occurs in approximately 25% of successfully treated patients. Two phase 3 randomized, double-blind trials were conducted at 154 sites in the United States, Canada, and Europe to compare fidaxomicin vs vancomycin in treating CDI. Patients with CDI received fidaxomicin 200 mg twice daily or vancomycin 125 mg 4 times daily for 10 days. The primary end point was clinical cure of CDI at end of treatment, and a secondary end point was recurrence during the 28 days following clinical cure. In all, 1164 subjects were enrolled, of which a subgroup of 128 in the per-protocol population had another recent episode of CDI prior to the CDI diagnosis at study enrollment. In the analysis of this subgroup, initial response to therapy was similar for both drugs (>90% cure). However, recurrence within 28 days occurred in 35.5% of patients treated with vancomycin and 19.7% of patients treated with fidaxomicin (-15.8% difference; 95% confidence interval, -30.4% to -0.3%; P = .045). Early recurrence (within 14 days) was reported in 27% of patients treated with vancomycin and 8% of patients treated with fidaxomicin (P = .003). In patients with a first recurrence of CDI, fidaxomicin was similar to vancomycin in achieving a clinical response at end of therapy but superior in preventing a second recurrence within 28 days.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585
Self-citationDecreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010
Kyne, L., Warny, M., Qamar, A., & Kelly, C. P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03592-3 · Cited by 804
Increasing Risk of Relapse after Treatment of Clostridium difficile Colitis in Quebec, Canada
Pepin, J., Alary, M.-E., Valiquette, L., Raiche, E., Ruel, J., Fulop, K., Godin, D., & Bourassa, C. (2005) · Clinical Infectious Diseases · doi:10.1086/430315 · Cited by 570
Aas, J., Gessert, C. E., & Bakken, J. S. (2003) · Clinical Infectious Diseases · doi:10.1086/367657 · Cited by 518
Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes
Johnson, S. (2009) · Journal of Infection · doi:10.1016/j.jinf.2009.03.010 · Cited by 397
Bauer, M. P., Kuijper, E. J., & van Dissel, J. T. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.03099.x · Cited by 366
Epidemiology of Recurrences or Reinfections of Clostridium difficile -Associated Diarrhea
Barbut, F., Richard, A., Hamadi, K., Chomette, V., Burghoffer, B., & Petit, J.-C. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.6.2386-2388.2000 · Cited by 355
Johnson, S., Schriever, C., Galang, M., Kelly, C. P., & Gerding, D. N. (2007) · Clinical Infectious Diseases · doi:10.1086/511870 · Cited by 312
Probiotics for treatment of Clostridium difficile-associated colitis in adults
Pillai, A., & Nelson, R. L. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004611.pub2 · Cited by 251
Pepin, J., Routhier, S., Gagnon, S., & Brazeau, I. (2006) · Clinical Infectious Diseases · doi:10.1086/501126 · Cited by 246
Al-Nassir, W. N., Sethi, A. K., Li, Y., Pultz, M. J., Riggs, M. M., & Donskey, C. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00090-08 · Cited by 242
Hecht, D. W., Galang, M. A., Sambol, S. P., Osmolski, J. R., Johnson, S., & Gerding, D. N. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01623-06 · Cited by 228
Tannock, G. W., Munro, K., Taylor, C., Lawley, B., Young, W., Byrne, B., Emery, J., & Louie, T. (2010) · Microbiology · doi:10.1099/mic.0.042010-0 · Cited by 217
Self-citationLouie, T. J., Emery, J., Krulicki, W., Byrne, B., & Mah, M. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01443-07 · Cited by 190
Self-citationRifampin and Rifaximin Resistance in Clinical Isolates of Clostridium difficile
O'Connor, J. R., Galang, M. A., Sambol, S. P., Hecht, D. W., Vedantam, G., Gerding, D. N., & Johnson, S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00342-08 · Cited by 187
Yoon, S. S., & Brandt, L. J. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181dac035 · Cited by 178
Recurrences of Clostridium difficile Diarrhea Not Caused by the Original Infecting Organism
Johnson, S., Adelmann, A., Clabots, C. R., Peterson, L. R., & Gerding, D. N. (1989) · Journal of Infectious Diseases · doi:10.1093/infdis/159.2.340 · Cited by 163
Curry, S. R., Marsh, J. W., Shutt, K. A., Muto, C. A., O’Leary, M. M., Saul, M. I., Pasculle, A. W., & Harrison, L. H. (2009) · Clinical Infectious Diseases · doi:10.1086/596315 · Cited by 156
The Microecology of Clostridium difficile
Wilson, K. H. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/16.supplement_4.s214 · Cited by 140
Nerandzic, M. M., Mullane, K. M., Miller, M. A., Babakhani, F., & Donskey, C. J. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis440 · Cited by 128
Self-citationFreeman, J., Baines, S. D., Saxton, K., & Wilcox, M. H. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm113 · Cited by 103
Shah, D. N., Dang, M.-D., Hasbun, R., Koo, H. L., Jiang, Z., DuPont, H. L., & Garey, K. W. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.10.28 · Cited by 100
Struggling with recurrent Clostridium difficile infections: is donor faeces the solution?
van Nood, E., Speelman, P., Kuijper, E. J., & Keller, J. J. (2009) · Eurosurveillance · doi:10.2807/ese.14.34.19316-en · Cited by 99
Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model
Baines, S. D., O'Connor, R., Saxton, K., Freeman, J., & Wilcox, M. H. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn502 · Cited by 83
Fidaxomicin (OPT-80) for the treatment ofClostridium difficileinfection
Miller, M. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.485614 · Cited by 63
Self-citationClostridium difficile: controversies and approaches to management
Bauer, M. P., van Dissel, J. T., & Kuijper, E. J. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32833229ce · Cited by 56
Cited by
McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1085 · Cited by 2,690
Clostridium difficile Infection
Leffler, D. A., & Lamont, J. T. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1403772 · Cited by 1,450
Debast, S. B., Bauer, M. P., & Kuijper, E. J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12418 · Cited by 1,215
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
Wilcox, M. H., Gerding, D. N., Poxton, I. R., Kelly, C., Nathan, R., Birch, T., Cornely, O. A., Rahav, G., Bouza, E., Lee, C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1602615 · Cited by 858
Self-citationClostridium difficile infection
Smits, W. K., Lyras, D., Lacy, D. B., Wilcox, M. H., & Kuijper, E. J. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.20 · Cited by 853
Metadata
- Authors
- Cornely, O. A., Miller, M. A., Louie, T. J., Crook, D. W., & Gorbach, S. L.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-07-02
- Volume
- 55
- Issue
- suppl 2
- Pages
- S154-S161
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2144282350
- Cited by
- 401
- References
- 28
- FWCI
- 16.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.